Selected article for: "ARDS respiratory distress syndrome and asymptomatic infection"

Author: van de Veerdonk, Frank L.; Netea, Mihai G.
Title: Blocking IL-1 to prevent respiratory failure in COVID-19
  • Cord-id: 08p122lw
  • Document date: 2020_7_18
  • ID: 08p122lw
    Snippet: COVID-19 is an emerging disease that can manifest itself as asymptomatic or mild respiratory tract infection in the majority of individuals, but in some, it can progress into severe pneumonia and acute respiratory distress syndrome (ARDS). Inflammation is known to play a crucial role in the pathogenesis of severe infections and ARDS and evidence is emerging that the IL-1/IL-6 pathway is highly upregulated in patients with severe disease. These findings open new avenues for host-directed therapie
    Document: COVID-19 is an emerging disease that can manifest itself as asymptomatic or mild respiratory tract infection in the majority of individuals, but in some, it can progress into severe pneumonia and acute respiratory distress syndrome (ARDS). Inflammation is known to play a crucial role in the pathogenesis of severe infections and ARDS and evidence is emerging that the IL-1/IL-6 pathway is highly upregulated in patients with severe disease. These findings open new avenues for host-directed therapies in patients with symptomatic SARS-CoV-2 infection and might in addition to antiviral treatment be enough to curb the currently unacceptably high morbidity and mortality associated with COVID-19.

    Search related documents:
    Co phrase search for related documents
    • active cytokine and macrophage activation: 1
    • active cytokine and macrophage activation syndrome: 1
    • acute respiratory syndrome and liver dysfunction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and liver enzyme elevation: 1, 2, 3, 4, 5
    • acute respiratory syndrome and long term effect: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and low lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • acute respiratory syndrome and lung histology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and macrophage activation syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • liver dysfunction and low lymphocyte count: 1
    • liver dysfunction and lymphocyte count: 1, 2, 3
    • liver dysfunction and macrophage activation: 1, 2
    • liver dysfunction and macrophage activation syndrome: 1, 2
    • liver enzyme and lymphocyte count: 1, 2, 3, 4, 5, 6
    • liver enzyme and macrophage activation: 1, 2
    • liver enzyme and macrophage activation syndrome: 1, 2
    • liver enzyme elevation and macrophage activation: 1